Globus Medical Inc. Class A Common Stock vs Liberty Energy Inc. Class A common stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Liberty Energy Inc. Class A common stock trades at $17.99 (market cap $2.94B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 3.5× Liberty Energy Inc. Class A common stock's market cap, and Liberty Energy Inc. Class A common stock pays a 2% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Liberty Energy Inc. Class A common stock for 6 Days on average.
| GMED | LBRT | |
|---|---|---|
Market Cap | $10.25B | $2.94B |
Volume | 1,059,528 | 3,507,840 |
Sector | Health | Energy |
52-Week High | $96.82 | $33.93 |
52-Week Low | $58.33 | $11.94 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $4.00B |
Dividend Yield | — | 2% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Liberty Energy (LBRT) trades at $19.11, up 0.68% today, with a bearish technical signal but strong analyst support. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue reached $4.01B in 2025, though net margins are thin at 2.92%. Valuation metrics like P/E of 25.82 and P/S of 0.75 suggest mixed attractiveness relative to profitability.
Outlook is cautiously optimistic given earnings momentum and a $28.38 consensus price target, but risks include margin pressure from rising costs and execution challenges in expanding into data center power. The stock's proximity to its 52-week low of $19.00 highlights downside vulnerability if Q3 results disappoint.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Liberty Energy provides completion services and technologies for onshore oil, natural gas, and geothermal producers in North America. It also offers distributed power and energy-storage solutions through Liberty Power Innovations.
Read more on LBRT →